PTC CLINIC
Informace pro odborníky

Karcinom prostaty je společně s očními nádory nejčastějším nádorovým onemocněním léčeným protonovou terapií. Recentní publikované práce popisující výsledky protonové terapie jsou:

1. Kubeš J, Haas A, Vondráček V, Andrlík M, Navrátil M, Sláviková S, Vítek P, Dědečková K, Prausová J, Ondrová B, Vinakurau Š, Grebenyuk A, Doležal T, Velacková B, Rosina J. Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes. Int J Radiat Oncol Biol Phys. 2021 Feb 12:S0360-3016(21)00189-9. doi: 10.1016/j.ijrobp.2021.02.014.
2. Iwata H, Ishikawa H, Takagi M Long-term outcomes of proton therapy for prostate cancer in Japan: a multi-institutional survey of the Japanese Radiation Oncology Study Group. Cancer Med. 2018 Mar;7(3):677-689. doi: 10.1002/cam4.1350. Epub 2018 Feb 14.
3. Takagi M, Demizu Y, Terashima K. Long-term outcomes in patients treated with proton therapy for localized prostate cancer. Cancer Med. 2017 Oct;6(10):2234-2243.
4. Bryant C, Smith TL, Henderson RH Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):422-34;
5. Colaco RJ, et al., Rectal Toxicity After Proton Therapy For Prostate Cancer: An Analysis of Outcomes of Prospective Studies Conducted at the University of Florida Proton Therapy Institute. Int J Radiat Oncol Biol Phys. 2014 Nov 5. pii: S0360-3016(14)04060-7;
6. Mendenhall NP, et al., Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):596-602.;
7. Henderson RH, et al., Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials. Acta Oncol. 2013 Apr;52(3):463-9.;
8. Hoppe BS, Nichols RC, Henderson RH, Morris CG, Williams CR, Costa J, Marcus RB Jr, Mendenhall WM, Li Z, Mendenhall NP. Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. Cancer. 2012 Jan 17. doi: 10.1002/cncr.27398.
9. Nichols RC Jr, Morris CG, Hoppe BS, Henderson RH, Marcus RB Jr, Mendenhall WM, Li Z, Williams CR, Costa JA, Mendenhall NP. Proton radiotherapy for prostate cancer is not associated with post-treatment testosterone suppression. Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1222-6.
10. Mendenhall NP, Li Z, Hoppe BS, Marcus RB Jr, Mendenhall WM, Nichols RC, Morris CG, Williams CR, Costa J, Henderson R. Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):213-21.
11. Henderson et al., Five-year outcomes from prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer. PTCOG 55, San Diego, USA
12. Spratt et al., Comparison of high-dose (86,4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate risk prostate cancer
13. Odražka a kol., Five year results of IMRT for prostate cancer – tumor control. Klin Onkol 2013; 26(6):415-20
14. Sheets NC, Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012 Apr 18;307(15):1611-20.
15. Kase Y. et al., A treatment planning comparison of passive-scattering and intensity-modulated proton therapy for typical tumor sites. J Radiat Res. 2012;53(2):272-80. Epub 2011 Dec 1.
16. Hartsell F. et al., Hypofractionated vs Standard Fractionated Proton Beam Therapy for Early-Stage Prostate Cancer: Interim Results of a Randomized Prospective Trial Oncology (Williston Park). 2015 Apr 21;29(4 Suppl 1).
17. Chung C. et al., Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1)
18. FANG, Penny, Rosemarie MICK, Curtiland DEVILLE, et al. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.Cancer [online]. 2015, 121(7): 1118-1127 [cit. 2015-12-02]. DOI: 10.1002/cncr.29148. ISSN 0008543x.
19. McGee L, et al., Outcomes in men with large prostates (≥ 60 cm(3)) treated with definitive proton therapy for prostate cancer. Acta Oncol. 2013 Apr;52(3):470-6.;
20. Hoppe BS, et al., Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. Cancer. 2012 Sep 15;118(18):4619-26.

Odkazy:

1. Mendenhall NP, et al., Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):596-602.;
2. Takagi M, Demizu Y, Terashima K. Long-term outcomes in patients treated with proton therapy for localized prostate cancer. Cancer Med. 2017 Oct;6(10):2234-2243.
3. Bryant C, Smith TL, Henderson RH Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):422-34;
4. Iwata H, Ishikawa H, Takagi M Long-term outcomes of proton therapy for prostate cancer in Japan: a multi-institutional survey of the Japanese Radiation Oncology Study Group. Cancer Med. 2018 Mar;7(3):677-689. doi: 10.1002/cam4.1350. Epub 2018 Feb 14.¨
5. Kubeš J, Haas A, Vondráček V, Andrlík M, Navrátil M, Sláviková S, Vítek P, Dědečková K, Prausová J, Ondrová B, Vinakurau Š, Grebenyuk A, Doležal T, Velacková B, Rosina J. Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes. Int J Radiat Oncol Biol Phys. 2021 Feb 12:S0360-3016(21)00189-9. doi: 10.1016/j.ijrobp.2021.02.014.
6. Spratt et al., Comparison of high-dose (86,4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate risk prostate cancer
7. Odrážka a kol., Five year results of IMRT for prostate cancer – tumor control. Klin Onkol 2013; 26(6):415-20